西酞普兰治疗广泛性焦虑症对照研究  

A control study of citalopram in the treatment of generalized anxiety disorder

作　　者：王飞[1] 

机构地区：[1]天津市公安局安康医院,中国·天津300240

出　　处：《临床心身疾病杂志》2011年第6期517-518,共2页Journal of Clinical Psychosomatic Diseases

摘　　要：目的 探讨西酞普兰治疗广泛性焦虑症的临床疗效及安全性.方法 将66例广泛性焦虑症患者随机分为两组,每组33例,研究组口服西酞普兰治疗,对照组口服劳拉西泮治疗,观察6周.于治疗前及治疗第1周、2周、4周、6周末采用汉密顿焦虑量表及焦虑自评量表评定临床疗效,副反应量表评定不良反应.结果 治疗后两组汉密顿焦虑量表及焦虑自评量表评分均较治疗前有显著下降（P＜0.05或0.01）,研究组治疗1周、2周、4周末均较对照组下降显著（P＜0.05或0.01）;治疗6周末,研究组显效率78.79%、有效率87.88%,对照组分别为72.73%、81.82%,研究组均高于对照组,但差异无显著性（χ2=0.33、0.47,P＞0.05）.两组不良反应较轻微,研究组主要表现为口干、白天困倦、胃肠不适、乏力;对照组主要表现为白天困倦、头晕、乏力.结论 西酞普兰治疗广泛性焦虑疗效显著,起效快,安全性高,依从性好,优于劳拉西泮治疗.Objective To explore the efficacy and safety of citalopram in the treatment of generalized anxiety disorder （GAD）. Methods Sixty-six GAD patients were randomly divided into two groups of 33 ones each, research group took orally citalopram and control group did lorazepam for 6 weeks. Clinical efficacies were assessed with the Hamilton Anxiety Scale （HAMA）, Self-rating Anxiety Scale （SAS） and adverse reacyions with the Treatment Emeregent Symptom Scale （TESS） before treatment and at the end of the 1st , 2nd, 4th and 6th week. Results After treatment the HAMA and SAS scores of both groups lowered more significantly compared with pretreatment （P〈0.05 or 0.01）, so did those in the rsearch than in the control group at the end of the 1st , 2nd and 4th week （P〈0. 05 or 0.01） ; at the end of the 6th week, obviuos effective and effective rates were 78.79% and 87.88% in the research and 72.73% and 81.82% in the control group, which showed no significant differences （P〉0.05）. Adverse reactions of both groups were mild, those were mainly dry mouth, daytime drowsiness, gastrointestinal upset and acratia in the research and daytime drowsiness, dizziness and acratia in the control group. Conclusion Citalopram has an advantage over lorazepam in efficacy, taking effect, safety and compliance in the treatment of generalized anxiety.

关 键 词：广泛性焦虑症 西酞普兰 劳拉西泮 汉密顿焦虑量表 焦虑自评量表 副反应量表 

分 类 号：R749.72[医药卫生—神经病学与精神病学] R749.053[医药卫生—临床医学]